However, our data indicate that NKp30-based CAR T cells can detect low to intermediate B7H6 expression, which, given our observations on differential B7H6 expression levels in AML, might facilitate anti-tumor reactivity not only to high B7H6-expressing tumors. The gene discussed is NCR3LG1; the disease is neoplasm.